Description
BPC-157 Oral is the oral tablet form of the well-known healing peptide BPC-157. The substance itself is identical with subcutaneously administered BPC-157, just formulated as tablet for oral use. A research application in adherence-oriented setups without subcutaneous injection.
Per study reports the pharmacology remains identical: pentadecapeptide of 15 amino acids with binding to growth hormone receptors in tendon fibroblasts, promotion of fibroblast migration, modulation of NO synthesis pathways, broad healing effects on tendons, ligaments, muscles, bones, skin, and gastrointestinal tract.
The central question with oral BPC-157 is bioavailability. Gastrointestinal enzymatic degradation substantially reduces systemic availability vs subcutaneous injection. The oral form compensates with higher doses - typically 500mcg-1mg per tablet vs 200-500mcg subcutaneous.
An interesting property: BPC-157 shows healing-promoting effects in the gastrointestinal tract itself. In GI-oriented research setups (inflammatory bowel disease models) the oral form is theoretically advantageous - direct local action at the target tissue.
Pharmacokinetically orally bioavailable with moderate to low systemic bioavailability. Half-life after absorption several hours.
You can order BPC-157 Oral as tablets in one bottle with 500mcg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
BPC-157 Oral is considered remarkably well tolerated per study reports. In preclinical studies on BPC-157, no significant toxic effects have been documented, and the oral tablet form additionally avoids injection-related reactions.
Observed in research and user reports:
- Gastrointestinal tract: as an oral form, mild transient gastrointestinal observations (fullness, loose stool) are the most likely. BPC-157 shows healing-promoting effects in the gastrointestinal tract itself, which supports local tolerability.
- Low systemic bioavailability: enzymatic degradation in the gastrointestinal tract substantially reduces systemic availability compared to the subcutaneous form - this is primarily an efficacy question, not a safety one.
- Circulation: isolated reports of brief fatigue or a feeling of warmth shortly after application.
- No long-term data: robust long-term human studies do not exist. The favorable safety profile rests primarily on animal models and short-term anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs - Frontiers in Pharmacology 2022, He et al: PK profile across oral and parenteral routes.
- A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC - Journal of Physiology-Paris 1993, Sikiric et al: original characterization with gastric focus, the basis for oral application.
- Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats - European Journal of Pharmacology 1999, Jelovac et al: intragastric administration in animal models.
- Stable gastric pentadecapeptide BPC 157 and wound healing - Frontiers in Pharmacology 2021, Seiwerth et al: classic mechanism review.
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing - Cell and Tissue Research 2019, Gwyer et al: healing effects on tendon and muscle.
